Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Jul 14:18:794-798.
doi: 10.12659/ajcr.903485.

Nilotinib Induced Recurrent Gastric Polyps: Case Report and Review of Literature

Nancy Kassem  1 , Omar M Ismail  2 , Halima Elomri  2 , Mohamad A Yassin  2
Affiliations
Review

Nilotinib Induced Recurrent Gastric Polyps: Case Report and Review of Literature

Nancy Kassem et al. Am J Case Rep. .

Abstract

BACKGROUND Tyrosine kinase inhibitors (TKIs) are currently an important targeted drug class in the treatment of chronic myeloid leukemia (CML). Imatinib was the first approved TKI for CML in 2001. Nilotinib is a second-generation TKI, approved in 2007; it inhibits BCR-ABL, PDGFR, and c-KIT, and is 30 times more potent than imatinib. Tyrosine kinase enzymes are expressed in multiple tissues and are involved in several signaling pathways; they have been shown to have several off-target side effects. CASE REPORT We report a case of an elderly male with CML and no history of gastrointestinal diseases, treated with nilotinib, and developed recurrent gastric polyps after three years of treatment. We excluded common causes of gastric polyps and therefore considered nilotinib as a probable cause of recurrent gastric polyps. CONCLUSIONS Recurrent gastric polyps could be a potential side effect of nilotinib treatment. Careful long-term monitoring of patients on TKI therapy is necessary and further long-term studies of TKI side effects are needed.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: None declared

Conflict of interest

None declared.

Figures

Figure 1.
Figure 1.
2 cm stalked polyp in the greater curvature.
Figure 2.
Figure 2.
Stomach with small cardiac hyperplastic polyp (same size as previous endoscopy).
See this image and copyright information in PMC

References

    1. Weisberg E, Manley PW, Breitenstein W, et al. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell. 2005;7:129–41. - PubMed
    1. Druker BJ, Guilhot F, O’Brien SG, et al. Five-year follow-up for patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006;355:2408–17. - PubMed
    1. Caldemeyer L, Dugan M, Edwards J, Akard L. Long-term side effects of tyrosine kinase inhibitors in chronic myeloid leukemia. Curr Hematol Malig Rep. 2016;11(2):71–79. - PubMed
    1. Baccarani M, Cortes J, Pane F, et al. Chronic myeloid leukemia: An update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol. 2009;27(35):6041–51. - PMC - PubMed
    1. Park DY, Lauwers GY. Gastric polyps classification and management. Arch Pathol Lab Med. 2008;132:633–40. - PubMed

MeSH terms